Novel technologies have the potential to allow us to treat more ailments, but often come at the price of new toxicities. Speaking from the International Conference of Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH ), Saar Gill, MD, PhD from the University of Pennsylvania, Philadelphia, PA discusses how stronger regulations and greater transparency between scientists, patients and physicians has impacted these new technologies. Dr Gill also highlights the necessity of controlling side effects and the importance of managing expectations.
The development of novel treatment modalities: regulations and expectations
